#ITI#Molecular characterization and typing of enrofloxacin-resistant clinical isolates of Mycoplasma gallisepticum#FTI#
#IRE#Emergence of resistance to fluoroquinolones is mainly due to chromosomal mutations in genes encoding the subunits of the drug's target enzymes, DNA gyrase and topoisomerase IV, which are essential for DNA replication. The quinolone resistance-determining regions (QRDRs) of these genes were characterized in 25 Mycoplasma gallisepticum strains isolated from commercial poultry flocks during 1997-2007, which exhibited different levels of susceptibility to fluoroquinolones. All enrofloxacin-resistant isolates harbored amino acid substitutions in the QRDRs of each of three proteins (GyrA, GyrB, and ParC). Molecular typing of those strains by random amplification of polymorphic DNA and gene-targeted sequencing supports ongoing, stepwise selection of resistant strains from the existing reservoir of susceptible M. gallisepticum strains.#FRE#
#IPC#Enrofloxacin; Molecular typing; Mycoplasma gallisepticum; Quinolone resistance-determining regions; Resistance#FPC#
#IRF#Bebear C.M., Bebear C., Antimycoplasmal agents, Molecular biology and pathogenicity of mycoplasmas, pp. 545-566, (2002); 
Bebear C.M., Renaudin H., Charron A., Clerc M., Pereyre S., Bebear C., DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones, Antimicrob. Agents Chemother, 47, pp. 3323-3325, (2003); 
Bebear C.M., Renaudin H., Charron A., Gruson D., Lefrancois M., Bebear C., In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized, Antimicrob. Agents Chemother, 44, pp. 2557-2560, (2000); 
Buyuktanyr O., Yyldyrym T., Yakycyer C., Genc O., Yurdusev N., A recombinant PvpA protein-based diagnostic prototype for rapid screening of chicken Mycoplasma gallisepticum infections, Vet. Microbiol, 129, pp. 139-149, (2007); 
Fan H.H., Kleven S.H., Jackwood M.W., Application of polymerase chain reaction with arbitrary primers to strain identification of Mycoplasma gallisepticum, Avian Dis, 39, pp. 729-735, (1995); 
Ferguson N.M., Hepp D., Sun S., Ikuta N., Levisohn S., Kleven S.H., Garcia M., Use of molecular diversity of Mycoplasma gallisepticum by gene-targeted sequencing (GTS) and random amplified polymorphic DNA (RAPD) analysis for epidemiological studies, Microbiology, 151, pp. 1883-1893, (2005); 
Geary S.J., Forsyth M.H., Saoud S.A., Wang G., Berg D.E., Berg C.M., Mycoplasma gallisepticum strain differentiation by arbitrary primer PCR (RAPD) fingerprinting, Mol. Cell. Probes, 8, pp. 311-316, (1994); 
Gerchman I., Lysnyansky I., Perk S., Levisohn S., In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkeys, Vet. Microbiol, 131, pp. 266-276, (2008); 
Hannan P.C., Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species, Vet. Res, 31, pp. 373-395, (2000); 
Hirose K., Kawasaki Y., Kotani K., Abiko K., Sato H., Characterization of a point mutation in the parC gene of Mycoplasma bovirhinis associated with fluoroquinolone resistance, J. Vet. Med. B, 51, pp. 169-175, (2004); 
Hong Y., Garcia M., Levisohn S., Lysnyansky I., Leiting V., Savelkoul P.H.M., Kleven S.H., Evaluation of amplified fragment length polymorphism for differentiation of avian mycoplasma species, J. Clin. Microbiol, 43, pp. 909-912, (2005); 
Hooper D.C., Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance, Clin. Infect. Dis, 27, (1998); 
Kleven S.H., Levisohn S., Mycoplasma infections of poultry, Molecular and diagnostic procedures in mycoplasmology, 2, pp. 283-292, (1996); 
Ley D.H., Berkhoff J.E., Levisohn S., Molecular epidemiological investigations of Mycoplasma gallisepticum (MG) conjunctivitis in songbirds by random amplified polymorphic DNA (RAPD) analyses, Emerg. Infect. Dis, 3, pp. 375-380, (1997); 
Morgan-Linnell S.K., Zechiedrich L., Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli, Antimicrob. Agents Chemother, 51, pp. 4205-4208, (2007); 
Development of in vitro susceptibility testing criteria and quality control parameters for veterinary antimicrobial agents, Approved guideline, 22, (2002); 
Pakpinyo S., Sasipreeyajan J., Molecular characterization and determination of antimicrobial resistance of Mycoplasma gallisepticum isolated from chickens, Vet. Microbiol, 125, pp. 59-65, (2007); 
Papazisi L., Gorton T.S., Kutish G., Markham P.F., Browning G.F., Nguyen D.K., Swartzell S., Madan A., Mahairas G., Geary S.J., The complete genome sequence of the avian pathogen Mycoplasma gallisepticum strain R(low), Microbiology, 149, pp. 2307-2316, (2003); 
Reinhardt A.K., Bebear C.M., Kobisch M., Kempf I., Gautier-Bouchardon A.V., Characterization of mutations in DNA gyrase and topoisomerase IV involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro, Antimicrob. Agents Chemother, 46, pp. 590-593, (2002); 
Reinhardt A.K., Kempf I., Kobisch M., Gautier-Bouchardon A.V., Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level, J. Antimicrob. Chemother, 50, pp. 589-592, (2002)#FRF#
